Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Sell the Bounce In Fitbit Inc (FIT) Stock

By Vince Martin, InvestorPlace Contributor
Fitbit Inc might look cheap, but it isn't. An unprofitable business and increasing competition mean FIT stock still has more downside.

The Bank of America Corp (BAC) Stock Rally Is Nearing Its End

By Dana Blankenhorn, InvestorPlace Contributor
Bank of America (BAC) is up 45% in hope of earnings gains that have not yet come. That could end up biting BAC stock, and sooner than later.

3 Dow Jones Stocks That Are Set Up for Failure

By Anthony Mirhaydari, InvestorPlace Market Strategist
With the Dow Jones' record uptrend at risk, these three stocks look vulnerable to a nasty pullback as momentum fades.

Don’t Waste Any More Time on Valeant Pharmaceuticals Intl Inc (VRX) Stock

By Dana Blankenhorn, InvestorPlace Contributor
Valeant (VRX) is in the position of a losing gambler trying to hock a watch, but VRX stock isn't going to fetch the price it wants.

Leave Sears Holdings Corp (SHLD) Stock to the Savages

By Dana Blankenhorn, InvestorPlace Contributor
Sears stock is undergoing a slow-motion liquidation while SHLD investors ask if there is even $1 billion in equity value left.

Target Corporation (TGT) Stock Is Even Worse Than Q4 Earnings Suggest

By James Brumley, InvestorPlace Feature Writer
Target (TGT) fell sharply following its Q4 earnings release, but the story behind TGT stock might be even worse than the raw numbers.

8 of the Most Overrated Stocks on Wall Street Right Now

By James Brumley, InvestorPlace Feature Writer
Some stocks are graded fairly, but a handful of the most overrated stocks deserve to be called out -- and sold sooner than later.

Valeant Pharmaceuticals Intl Inc (VRX) Stock Is the Twitter Inc (TWTR) of Pharma

By Josh Enomoto, InvestorPlace Contributor
The air is rife with comeback stories, but Valeant Pharmaceuticals faces an obscenely difficult task in returning VRX stock to greatness.

Valeant Pharmaceuticals Intl Inc (VRX) Q4 Earnings: What to Expect

By Richard Saintvilus, InvestorPlace Contributor
Valeant Pharmaceuticals (VRX) needs too many things to go right to emerge strong in 2017. VRX stock just doesn't control its own destiny.

Buy Fitbit Inc (FIT) Trackers, But Not Fitbit Stock

By Will Ashworth, InvestorPlace Contributor
Whether Fitbit (FIT) is at $5 or $50, investing in the future of Fitbit stock is a crap shoot at best, and a recipe for calamity at worst.

7 REITs That Should Be Condemned

By Louis Navellier, Editor, Growth Investor
REITs are set up so that they're required to pay out 90% of their income to shareholders. But beware: Not all REITs were created equal.

Why Freeport-McMoRan Inc (FCX) Stock Is Much Uglier Without Indonesia

By James Brumley, InvestorPlace Feature Writer
Freeport McMoRan (FCX) flinched first, effectively conceding that Indonesian regulators were holding all the cards with Papua's copper mine.

Should You Buy L Brands Inc Stock on the Dip? (LB)

By Louis Navellier, Editor, Growth Investor
L Brands recent earnings came in at expectations, but future guidance numbers have scared away investors in LB stock

Siliq Won’t Bring Valeant Pharmaceuticals Intl Inc (VRX) Stock Back to Life

By Chris Fraley, InvestorPlace Contributor
Valeant has lost nearly all its value in the last 18 months due to its involvement with a drug called Siliq -- can it also save VRX stock?

Drop Wal-Mart Stores Inc (WMT) Stock Before It Drops You

By Luke Lango, InvestorPlace Senior Investment Analyst
Walmart (WMT) soared after its fourth-quarter earnings report, but WMT stock feels overvalued given a mundane growth outlook.

3 Reasons Investors Should Steer Clear of Under Armour Inc (UA) Stock

By Marie Brodbeck, InvestorPlace Contributor
Under Armour does have some potential, but the year ahead looks like a rocky one and investors would be smart to avoid UA stock right now.

Fitbit Inc Reports Putrid Fourth-Quarter Earnings

By Tom Taulli, InvestorPlace Contributor
Fitbit (FIT) put together a dud of a Q4 that missed on the top and bottom lines, but FIT stock is actually rising Wednesday in response.

Why BlackBerry Ltd (BBRY) Stock Won’t Escape This Ditch Anytime Soon

By Richard Saintvilus, InvestorPlace Contributor
In order for BBRY stock to be a worthy investment, BlackBerry must do more than just show “proof of life” every once in a while.

Leave Under Armour Inc (UAA) Stock for Dead

By Lawrence Meyers, InvestorPlace Contributor
UAA is in a commodity business and Under Armour just cannot compete long-term with its rivals, like Nike (NKE).
Load More Articles